Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2020 Aug 21

PMID 32816215

Citations 6

Authors

Remo Panaccione

John D Isaacs

Lea Ann Chen

Wenjin Wang

Amy Marren

Kenneth Kwok

Lisy Wang

Gary Chan

Chinyu Su

Affiliations

Soon will be listed here.

Abstract

Background: Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Creatine kinase (CK) levels and CK-related adverse events (AEs) in tofacitinib-treated patients with UC were evaluated.

Methods: Data were analyzed for three UC cohorts: Induction (phase 2 and 3 induction studies); Maintenance (phase 3 maintenance study); Overall [patients who received tofacitinib 5 or 10 mg twice daily (b.d.) in phase 2, phase 3, or open-label, long-term extension studies; data at November 2017]. Clinical trial data for tofacitinib-treated patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis are presented for contextualization.

Results: Week 8 mean change from baseline CK with tofacitinib 10 mg b.d. induction therapy was 91.1 U/L (95% CI, 48.1-134.1) versus 19.2 U/L (8.5-29.9) with placebo. Among patients completing induction with 10 mg b.d. and re-randomized to 52 weeks of maintenance therapy, mean increases from induction baseline to the end of maintenance were 35.9 (8.1-63.7), 90.3 (51.9-128.7), and 115.6 U/L (91.6-139.7), with placebo, 5 and 10 mg b.d., respectively. The incidence rate (unique patients with events per 100 patient-years) for AEs of CK elevation in the tofacitinib-treated UC Overall cohort was 6.6 versus 2.2, 6.5, and 3.7 for tofacitinib-treated patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis, respectively. No serious AEs of CK elevation or AEs of myopathy occurred in UC studies.

Conclusions: In patients with UC, CK elevations with tofacitinib appeared reversible and not associated with clinically significant AEs. UC findings were consistent with tofacitinib use in other inflammatory diseases.

Trial Registration: NCT00787202; NCT01465763; NCT01458951; NCT01458574; NCT01470612; NCT01262118; NCT01484561; NCT00147498; NCT00413660; NCT00550446; NCT00603512; NCT00687193; NCT01059864; NCT01164579; NCT00976599; NCT01359150; NCT02147587; NCT00960440; NCT00847613; NCT00814307; NCT00856544; NCT00853385; NCT01039688; NCT02187055; NCT00413699; NCT00661661; NCT01710046; NCT00678210; NCT01276639; NCT01309737; NCT01241591; NCT01186744; NCT01163253; NCT01877668; NCT01882439; NCT01976364.

Citing Articles

Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis.

Xiong G, Yu E, Heung M, Yang J, Lowe M, Abu-Hilal M JAAD Int. 2025; 19:1-9.

PMID: 39872731 PMC: 11763511. DOI: 10.1016/j.jdin.2024.11.009.

Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.

Szekanecz Z, Buch M, Charles-Schoeman C, Galloway J, Karpouzas G, Kristensen L Nat Rev Rheumatol. 2024; 20(2):101-115.

PMID: 38216757 DOI: 10.1038/s41584-023-01062-9.

Effects of Tofacitinib on Muscle Remodeling in Experimental Rheumatoid Sarcopenia.

Bermejo-Alvarez I, Perez-Baos S, Gratal P, Medina J, Largo R, Herrero-Beaumont G Int J Mol Sci. 2023; 24(17).

PMID: 37685986 PMC: 10487422. DOI: 10.3390/ijms241713181.

Before Blaming Legionella for Severe Rhabdomyolysis, Consider Alternative Triggers.

Finsterer J, Scorza F, de Almeida A J Community Hosp Intern Med Perspect. 2023; 13(1):58-59.

PMID: 36846074 PMC: 9949725. DOI: 10.55729/2000-9666.1148.

Immensely High Creatine Kinase Levels in a Case of Rhabdomyolysis Due to Legionnaires' Disease in a Patient on Tofacitinib: A Case Report and Literature Review.

Gopalakrishna H, Al-Abdouh A, Nair G, Solipuram V, Bekele A J Community Hosp Intern Med Perspect. 2022; 12(2):45-49.

PMID: 35712689 PMC: 9195066. DOI: 10.55729/2000-9666.1038.

References

Lee E, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D . Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014; 370(25):2377-86. DOI: 10.1056/NEJMoa1310476. View

Papp K, Menter A, Strober B, Langley R, Buonanno M, Wolk R . Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012; 167(3):668-77. DOI: 10.1111/j.1365-2133.2012.11168.x. View

Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Koutroubakis I . Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018; 24(6):1266-1271. DOI: 10.1093/ibd/izy088. View

Brancaccio P, Maffulli N, Limongelli F . Creatine kinase monitoring in sport medicine. Br Med Bull. 2007; 81-82:209-30. DOI: 10.1093/bmb/ldm014. View

Kyriakides T, Angelini C, Schaefer J, Sacconi S, Siciliano G, Vilchez J . EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol. 2010; 17(6):767-73. DOI: 10.1111/j.1468-1331.2010.03012.x. View

Fleischmann R, Pangan A, Song I, Mysler E, Bessette L, Peterfy C . Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019; 71(11):1788-1800. DOI: 10.1002/art.41032. View

Kremer J, Kivitz A, Simon-Campos J, Nasonov E, Tony H, Lee S . Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. Arthritis Res Ther. 2015; 17:95. PMC: 4445792. DOI: 10.1186/s13075-015-0612-7. View

Mease P, Hall S, FitzGerald O, van der Heijde D, Merola J, Avila-Zapata F . Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017; 377(16):1537-1550. DOI: 10.1056/NEJMoa1615975. View

Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich S . Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011; 63(8):1150-8. DOI: 10.1002/acr.20494. View

10.

Moghadam-Kia S, Oddis C, Aggarwal R . Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med. 2016; 83(1):37-42. PMC: 4871266. DOI: 10.3949/ccjm.83a.14120. View

11.

Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S . Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2014; 25(4):514-21. PMC: 4819568. DOI: 10.3109/14397595.2014.995875. View

12.

van Vollenhoven R, Fleischmann R, Cohen S, Lee E, Garcia Meijide J, Wagner S . Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367(6):508-19. DOI: 10.1056/NEJMoa1112072. View

13.

Kremer J, Bloom B, Breedveld F, Coombs J, Fletcher M, Gruben D . The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009; 60(7):1895-905. DOI: 10.1002/art.24567. View

14.

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell C, Bradley J . Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012; 367(6):495-507. DOI: 10.1056/NEJMoa1109071. View

15.

Ordas I, Feagan B, Sandborn W . Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012; 10(10):1079-87. DOI: 10.1016/j.cgh.2012.06.032. View

16.

Lilleng H, Abeler K, Johnsen S, Stensland E, Loseth S, Jorde R . Variation of serum creatine kinase (CK) levels and prevalence of persistent hyperCKemia in a Norwegian normal population. The Tromsø Study. Neuromuscul Disord. 2011; 21(7):494-500. DOI: 10.1016/j.nmd.2011.04.007. View

17.

Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S . Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016; 18:34. PMC: 4730592. DOI: 10.1186/s13075-016-0932-2. View

18.

Winthrop K, Silverfield J, Racewicz A, Neal J, Lee E, Hrycaj P . The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2015; 75(4):687-95. PMC: 4819610. DOI: 10.1136/annrheumdis-2014-207191. View

19.

Bissonnette R, Iversen L, Sofen H, Griffiths C, Foley P, Romiti R . Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2014; 172(5):1395-406. DOI: 10.1111/bjd.13551. View

20.

Chavez L, Leon M, Einav S, Varon J . Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016; 20(1):135. PMC: 4908773. DOI: 10.1186/s13054-016-1314-5. View